GoldenGolden
Advanced Search
Eloxx Pharmaceuticals

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is a rare Genetic Diseases.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

June 2017
Eloxx Pharmaceuticals raises a $5,000,000 series C round from DSC Investments, GF Securities, Korea Investment Partners, OPKO Health, Phillip Frost, Pontifax Venture Capital and Quark Venture Capital.

Funding rounds

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
April 1, 2021
FierceBiotech
Eloxx Pharmaceuticals had a tough 2020, starting out the year cutting staffers and hiring a new chief, and then had a stop-start relationship with its midstage cystic fibrosis trial amid COVID-19 chaos.
BioSpace
October 22, 2020
BioSpace
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC).
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.